SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma - Quaterly Results

12 Aug 2025 Evaluate
The sales figure stood at Rs. 3197.34 millions for the June 2025 quarter. The mentioned figure indicates a growth of about 25.62% as compared to Rs. 2545.27 millions during the year-ago period.Net profit for the quarter ended June 2025 increased significantly by 50.10% to Rs. 480.56 millions from Rs. 320.15 millions.The company reported a good operating profit of 720.64 millions compared to 494.18 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 3197.34 2545.27 25.62 3197.34 2545.27 25.62 11743.74 8532.73 37.63
Other Income 20.10 81.52 -75.34 20.10 81.52 -75.34 698.34 620.73 12.50
PBIDT 720.64 494.18 45.83 720.64 494.18 45.83 2738.85 2020.08 35.58
Interest 3.02 2.83 6.71 3.02 2.83 6.71 11.74 9.88 18.83
PBDT 717.62 491.35 46.05 717.62 491.35 46.05 2727.11 2010.20 35.66
Depreciation 81.88 68.36 19.78 81.88 68.36 19.78 294.52 291.28 1.11
PBT 635.74 422.99 50.30 635.74 422.99 50.30 2432.59 1718.92 41.52
TAX 155.18 102.84 50.89 155.18 102.84 50.89 549.87 381.34 44.19
Deferred Tax 9.80 -0.74 -1424.32 9.80 -0.74 -1424.32 28.43 6.78 319.32
PAT 480.56 320.15 50.10 480.56 320.15 50.10 1882.72 1337.58 40.76
Equity 453.16 453.16 0.00 453.16 453.16 0.00 453.16 453.16 0.00
PBIDTM(%) 22.54 19.42 16.09 22.54 19.42 16.09 23.32 23.67 -1.49

Marksans Pharma Share Price

180.50 1.60 (0.89%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×